These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 16218488)

  • 21. Nonsteroidal Anti-Inflammatory Drugs: Exploiting Bivalent COXIB/ TP Antagonists for the Control of Cardiovascular Risk.
    Carnevali S; Buccellati C; Bolego C; Bertinaria M; Rovati GE; Sala A
    Curr Med Chem; 2017; 24(30):3218-3230. PubMed ID: 28571535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Valat JP; Deray G; Héloire F
    Presse Med; 2006 Sep; 35 Suppl 1():25-34. PubMed ID: 17870550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
    Moore RA; Derry S; McQuay HJ
    BMC Musculoskelet Disord; 2007 Aug; 8():73. PubMed ID: 17683540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cardiovascular toxicity of selective COX-2-inhibitors and classical NSAIDs].
    Lange H; Eberhart L
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2007 Jul; 42(7):514-7. PubMed ID: 17661262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now.
    Patrono C; Baigent C
    Clin Pharmacol Ther; 2017 Aug; 102(2):238-245. PubMed ID: 28378879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular Safety and Bleeding Risk Associated with Nonsteroidal Anti-Inflammatory Medications in Patients with Cardiovascular Disease.
    Ross SJ; Elgendy IY; Bavry AA
    Curr Cardiol Rep; 2017 Jan; 19(1):8. PubMed ID: 28138824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [What is new about nonsteroidal antiinflamatory drugs?].
    Dzielska-Olczak M
    Pol Merkur Lekarski; 2007 Dec; 23(138):454-8. PubMed ID: 18432131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of nonsteroidal anti-inflammatory drug-induced ulcer: looking to the future.
    Fiorucci S
    Gastroenterol Clin North Am; 2009 Jun; 38(2):315-32. PubMed ID: 19446261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts.
    Tacconelli S; Bruno A; Grande R; Ballerini P; Patrignani P
    Expert Opin Drug Saf; 2017 Jul; 16(7):791-807. PubMed ID: 28569569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk].
    Bijlsma JW
    Ned Tijdschr Geneeskd; 2004 Oct; 148(44):2162-4. PubMed ID: 15559407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular risks of cyclooxygenase inhibition.
    Stacy ZA; Dobesh PP; Trujillo TC
    Pharmacotherapy; 2006 Jul; 26(7):919-38. PubMed ID: 16803424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is the cardiovascular toxicity of NSAIDS and COX-2 selective inhibitors underestimated in patients with haemophilia?
    Boban A; Lambert C; Hermans C
    Crit Rev Oncol Hematol; 2016 Apr; 100():25-31. PubMed ID: 26899022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COX-2 inhibition: what we learned--a controversial update on safety data.
    Katz JA
    Pain Med; 2013 Dec; 14 Suppl 1():S29-34. PubMed ID: 24373107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk-benefit perspectives in COX-2 blockade.
    Dabu-Bondoc S; Franco S
    Curr Drug Saf; 2008 Jan; 3(1):14-23. PubMed ID: 18690976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonsteroidal anti-inflammatory drugs in clinical and experimental epilepsy.
    Radu BM; Epureanu FB; Radu M; Fabene PF; Bertini G
    Epilepsy Res; 2017 Mar; 131():15-27. PubMed ID: 28212985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-steroidal anti-inflammatory drugs and the risk of cardiovascular diseases: are we going to see the revival of cyclooxygenase-2 selective inhibitors?
    Głuszko P; Bielińska A
    Pol Arch Med Wewn; 2009 Apr; 119(4):231-5. PubMed ID: 19413182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk.
    Hermann M; Ruschitzka F
    Intern Med J; 2006 May; 36(5):308-19. PubMed ID: 16650196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups.
    Solomon DH; Glynn RJ; Rothman KJ; Schneeweiss S; Setoguchi S; Mogun H; Avorn J; Stürmer T
    Arthritis Rheum; 2008 Aug; 59(8):1097-104. PubMed ID: 18668605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond.
    Coruzzi G; Venturi N; Spaggiari S
    Acta Biomed; 2007 Aug; 78(2):96-110. PubMed ID: 17933277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Appropriate use of NSAIDs: considering cardiovascular risk in the elderly.
    Stillman MJ; Stillman MT
    Geriatrics; 2007 Mar; 62(3):16-21. PubMed ID: 17346094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.